U. S. NUCLEAR REGULATORY COMMISSION
|Office of Public Affairs||Telephone: 301/415-8200|
|Washington, DC 20555-001||E-mail: firstname.lastname@example.org|
July 23, 1998
TO MEDICAL POLICY STATEMENT, REGULATIONS
The Nuclear Regulatory Commission will convene public meetings in San Francisco, Kansas City, and Rockville, Maryland, over the next few months to obtain comments on the agency's proposed revisions to its policy statement and regulations on medical uses of licensed radioactive material.
The San Francisco meeting will be held on August 19 and 20 at the ANA Hotel San Francisco, 50 Third Street, San Francisco, California 94103; telephone: 415/974-6400.
The Kansas City meeting will be held on September 16 and 17 at the Radisson Suite Hotel Kansas City, 106 West 12th Street, Kansas City, Missouri 64105; telephone: 800/333-3333.
The Rockville meeting will be held on October 21 and 22 in the auditorium at the U.S. Nuclear Regulatory Commission, 11545 Rockville Pike, Rockville, MD 20852-2738.
All three meetings are scheduled for 8:30 a.m. to 5:00 p.m. each day.
Copies of the proposed revisions to the Commission's medical use policy statement and regulations will be provided to meeting participants and will be available for members of the public at the meetings. The proposed revisions are scheduled to be published in the Federal Register for public comment in August.
To have a manageable discussion, the number of participants in each meeting will be limited. Questions about participation should be directed to the meeting facilitator, Francis X. Cameron, Special Counsel for Public Liaison, Office of the General Counsel, Nuclear Regulatory Commission, Washington, D.C. 20555, telephone: 301/415-1642. Participation is expected by a broad spectrum of interests that may be affected by the proposed revisions to the regulations and policy statement. These interests include: physician specialists, such as nuclear medicine physicians, radiation oncologists, cardiologists and radiologists; medical physicists; medical technologists; nurses; medical education and certification organizations; radiopharmaceutical interests; hospital administrators; radiation safety officers; patients' rights advocates; states and federal agencies; and experts in risk analysis. Other members of the public are welcome to attend and will have an opportunity to participate in the meeting discussions at periodic intervals.
Written comments on the forthcoming proposed policy statement and rule revisions may be submitted to the Secretary, U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, Attention: Rulemakings and Adjudications Staff. To ensure consideration, comments should be received by the dates announced in the Federal Register notices.